Clinical Research Directory
Browse clinical research sites, groups, and studies.
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
Sponsor: Kyoto University, Graduate School of Medicine
Summary
The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous coronary intervention (PCI) using cobalt-chromium everolimus-eluting stents (CoCr-EES, XienceTM) in patients with high bleeding risk or under the acute coronary syndrome patients.
Official title: ShorT and OPtimal Duration of Dual AntiPlatelet Therapy Study After Everolimus-eluting Cobalt-chromium Stent-3
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
6002
Start Date
2021-01-29
Completion Date
2025-12-31
Last Updated
2024-06-14
Healthy Volunteers
No
Conditions
Interventions
No aspirin
1-month prasugrel monotherapy followed by clopidogrel monotherapy
1-month DAPT
1-month dual antiplatelet therapy comprising of aspirin and prasugrel followed by aspirin monotherapy
Locations (1)
Kyoto University Graduate School of Medicine
Kyoto, Japan